Bio-Rad Laboratories (BIO) Operating Leases (2019 - 2026)

Bio-Rad Laboratories (BIO) has 8 years of Operating Leases data on file, last reported at $138.6 million in Q1 2026.

• On a quarterly basis, Operating Leases rose 9.74% year-over-year to $138.6 million in Q1 2026; TTM through Mar 2026 was $138.6 million, a 9.74% increase from a year earlier, with the FY2025 full-year figure at $145.7 million, down 15.83% from the prior year.
• Operating Leases for Q1 2026 stood at $138.6 million, down from $145.7 million in the prior quarter.
• Over the last five years, Operating Leases for BIO reached as high as $206.3 million in Q3 2023 and fell as low as $126.3 million in Q1 2025.
• Historically, Operating Leases has averaged $169.1 million across 5 years, with a median of $169.7 million in 2022.
• Across the five-year window, Operating Leases jumped 40.14% in 2023 and tumbled 30.25% in 2024, its largest moves.
• Year by year, Operating Leases stood at $189.9 million in 2022, then grew by 8.43% to $205.9 million in 2023, then dropped by 15.93% to $173.1 million in 2024, then fell by 15.83% to $145.7 million in 2025, then decreased by 4.87% to $138.6 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $138.6 million in Q1 2026, $145.7 million in Q4 2025, and $192.6 million in Q3 2025.